全文获取类型
收费全文 | 2508830篇 |
免费 | 175762篇 |
国内免费 | 5005篇 |
专业分类
耳鼻咽喉 | 36634篇 |
儿科学 | 78462篇 |
妇产科学 | 71715篇 |
基础医学 | 356571篇 |
口腔科学 | 72691篇 |
临床医学 | 214879篇 |
内科学 | 489505篇 |
皮肤病学 | 54785篇 |
神经病学 | 199098篇 |
特种医学 | 99126篇 |
外国民族医学 | 788篇 |
外科学 | 389271篇 |
综合类 | 54524篇 |
现状与发展 | 7篇 |
一般理论 | 787篇 |
预防医学 | 180283篇 |
眼科学 | 58986篇 |
药学 | 189006篇 |
5篇 | |
中国医学 | 5168篇 |
肿瘤学 | 137306篇 |
出版年
2018年 | 24469篇 |
2016年 | 21299篇 |
2015年 | 24248篇 |
2014年 | 33833篇 |
2013年 | 51200篇 |
2012年 | 68994篇 |
2011年 | 73698篇 |
2010年 | 43650篇 |
2009年 | 41619篇 |
2008年 | 70533篇 |
2007年 | 76391篇 |
2006年 | 77278篇 |
2005年 | 75698篇 |
2004年 | 72777篇 |
2003年 | 70280篇 |
2002年 | 69158篇 |
2001年 | 110499篇 |
2000年 | 113417篇 |
1999年 | 96797篇 |
1998年 | 27787篇 |
1997年 | 24969篇 |
1996年 | 24449篇 |
1995年 | 23092篇 |
1994年 | 21819篇 |
1993年 | 20063篇 |
1992年 | 76551篇 |
1991年 | 74732篇 |
1990年 | 73519篇 |
1989年 | 71725篇 |
1988年 | 66854篇 |
1987年 | 65673篇 |
1986年 | 62776篇 |
1985年 | 59813篇 |
1984年 | 44980篇 |
1983年 | 38647篇 |
1982年 | 23449篇 |
1981年 | 21022篇 |
1979年 | 42791篇 |
1978年 | 30551篇 |
1977年 | 26425篇 |
1976年 | 24440篇 |
1975年 | 27238篇 |
1974年 | 32237篇 |
1973年 | 31169篇 |
1972年 | 29845篇 |
1971年 | 27756篇 |
1970年 | 26055篇 |
1969年 | 25129篇 |
1968年 | 23633篇 |
1967年 | 20942篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
Quality of life in stroke survivor–caregiver dyads: a new conceptual framework and longitudinal study protocol 下载免费PDF全文
22.
23.
24.
25.
26.
27.
28.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献
29.
30.
Mina Jane Zafar Thomas Kallemose Mostafa Benyahia Lars Bo Ebskov Jeannette
stergaard Penny 《Acta orthopaedica》2020,91(4):444
Background and purpose — Total ankle arthroplasties (TAAs) have larger revision rates than hip and knee implants. We examined the survival rates of our primary TAAs, and what different factors, including the cause of arthritis, affect the success and/or revision rate.Patients and methods — From 2004 to 2016, 322 primary Hintegra TAAs were implanted: the 2nd generation implant from 2004 until mid-2007 and the 3rd generation from late 2007 to 2016. A Cox proportional hazards model evaluated sex, age, primary diagnosis, and implant generation, pre- and postoperative angles and implant position as risk factors for revision.Results — 60 implants (19%) were revised, the majority (n = 34) due to loosening. The 5-year survival rate (95% CI) was 75% (69–82) and the 10-year survival rate was 68% (60–77). There was a reduced risk of revision, per degree of increased postoperative medial distal tibial angle at 0.84 (0.72–0.98) and preoperative talus angle at 0.95 (0.90–1.00), indicating that varus ankles may have a larger revision rate. Generation of implant, sex, primary diagnosis, and most pre- and postoperative radiological angles did not statistically affect revision risk.Interpretation — Our revision rates are slightly above registry rates and well above those of the developer. Most were revised due to loosening; no difference was demonstrated with the 2 generations of implant used. Learning curve and a low threshold for revision could explain the high revision rate.Arthritis in the ankle often develops earlier than in the hip or knee, and 70% have a traumatic etiology (Saltzman et al. 2005, Brown et al. 2006). Total ankle arthroplasty (TAA) can be indicated for severe arthritis in the ankle joint, but the anatomical preconditions, like a small surface area and high stress from compression and torque (Bouguecha et al. 2011, Kakkar and Siddique 2011), makes it less durable than hip and knee prosthetics. The Hintegra TAA, a 3-component mobile bearing, uncemented implant (Hintermann et al. 2004) is widely used and results from the development center demonstrate survival rates of 94% and 84% after 5 and 10 years’ follow-up (Barg et al. 2013). This is considerably more than the survival rates from national registries. Labek et al. (2011) demonstrated that development centers report only half of the revision rate that can be found in the few existing national registers. In a systematic review of primary Agility total ankle arthroplasty (DePuy Synthes Orthopedics, Warsaw, IN, USA), the author (Roukis 2012) found that the incidence of complications increased from 7% to 12%, in studies where the inventor was excluded. Similar results were found by Prissel and Roukis (2013), who found an increased incidence of complications from 6% to 13% in studies where the inventor or faculty consultants were excluded. These studies indicated the risk of selection (inventor) and publication (conflict of interest) bias.Planning and surgical technique, including significant experience, are mandatory for a successful outcome. The better result from development centers may reflect, besides the above-mentioned bias, that there is a long learning curve and that the indication for revision surgery varies.We examined the survival rates of primary Hintegra TAAs performed at Hvidovre Hospital, with revision rate as outcome. We report primary diagnosis for primary TAA and examine whether sex, generation of the implant, preoperative angles and implant position affect the revision rate. 相似文献